ELABElevai Labs Inc.

Nasdaq elevailabs.com


$ 0.34 $ 0.01 (2.13 %)    

Tuesday, 17-Sep-2024 12:42:03 EDT
QQQ $ 473.83 $ 0.25 (0.05 %)
DIA $ 417.12 $ -0.12 (-0.03 %)
SPY $ 563.14 $ 0.23 (0.04 %)
TLT $ 100.82 $ -0.49 (-0.48 %)
GLD $ 237.35 $ -1.32 (-0.55 %)
$ 0.3161
$ 0.35
-- x --
-- x --
$ 0.33 - $ 0.35
$ 0.22 - $ 4.24
364,198
na
6.38M
$ 0.85
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-29-2024 12-31-2023 10-K
4 12-11-2023 09-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Case Studies Highlight Potential of Elevai Exosome Technology in Melasma Care When Used with Laser Therapy. Early Results Sh...

Core News & Articles

Elevai Labs, Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announce...

Core News & Articles

Elevai Labs (NASDAQ:ELAB) reported quarterly losses of $(0.08) per share. This is a 37.5 percent increase over losses of $(0.13...

Core News & Articles

Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced...

Core News & Articles

Elevai Labs (NASDAQ:ELAB) reported quarterly losses of $(0.08) per share. This is a 27.03 percent increase over losses of $(0.1...

Core News & Articles

Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION